OF THE
TIMES
The long-term benefits of these drugs could be monumental in our approach to tackling obesity. For many people, these weight-loss jabs will be life-changing, help them get back to work, and ease the demands on our NHS.The specific drug in question is "Mounjaro", produced by pharma giant Lilly to compete with the Novo Nordisk's Ozempic/ Wegovy. And the first phase of the scheme is a five-year trial on 3000 obese people in the Manchester area, described in another Telegraph article:
Up to 3,000 obese patients - a mixture of those in and out of work, and on sickness leave - will be recruited for a five-year study that will explore whether the medication boosts productivity and could bring more people back to the workplace.It was also announced that Lilly - the biggest of Big Pharma vultures - will be "investing" ยฃ280 million in the scheme.
a collaboration that includes exploring new ways of delivering health and care services to people living with obesity, and a five-year real-world study of a cutting-edge obesity treatment.""Collaboration" is doing some work in that sentence.
Comment: Could it be that the Covid vaccine failure has opened peoples' eyes?